The Ethical Limits of Randomised Controlled Trials
Evidence-based medicine has elevated the randomised controlled trial to the position of gold standard for evaluating medical interventions. The methodological gains are real. The framework also generates ethical tension that is not always addressed, particularly where a physiological deficit is measurable and its corrective substrate is known.
The placebo group problem
An RCT allocates one group of participants to an active intervention and another to a placebo. The design is justified when the efficacy of the intervention is genuinely uncertain relative to the standard of care. It is not equally justified when the participant carries a documented deficit and the intervention is the substrate that corrects it.
Two doctrinal instruments already speak to this. The Nuremberg Code, promulgated in 1947 after the Doctors’ Trial, requires that human experimentation avoid all unnecessary physical and mental suffering and injury, and that no experiment be conducted where there is prior reason to believe serious harm will occur. The Declaration of Helsinki, in the 2013 revision of paragraph 33, requires that any new intervention be tested against the best proven intervention. A placebo control is permissible only where no proven intervention exists, or under compelling and scientifically sound methodological reasons, and never where patients would be exposed to additional risks of serious or irreversible harm from being deprived of the effective intervention. Where the deficit is documented and the substrate that corrects it is known, the placebo arm falls outside the conditions Helsinki §33 sets for it.
Waiting for evidence, and its cost
Evidence-based medicine typically requires robust trial evidence before an intervention is recommended. That process takes years, sometimes decades. During that period, people carrying measurable deficits go uncorrected, not because their deficit is contested but because the trial that would formalise the correction has not been funded or completed.
The right to health, read against the core obligations of General Comment 14 §43, does not authorise this delay for substrates that are inexpensive, available, and known to correct a documented deficit. The floor is not the moment at which a trial concludes. The floor is the moment at which the deficit is measurable and the correction is trivial.
The precautionary principle, applied to physiology
The absence of trial closure is not, in general, treated as licence for institutional inaction. In European Union law, the precautionary principle codified in Article 191 of the Treaty on the Functioning of the European Union authorises protective action in the face of serious risk even where scientific certainty is incomplete. The principle was developed in environmental policy and has been extended in the case law of the Court of Justice to public health matters, notably in the BSE and pharmaceutical safety line of decisions. Its logic transposes directly to physiological deficits: where the harm from inaction is documented and the corrective substrate is safe and available, the burden shifts toward acting rather than waiting.
Read together, the Nuremberg Code, Helsinki §33, and Article 191 TFUE describe a doctrinal architecture in which the deprivation of a known-effective corrective substrate, whether inside a trial or inside routine practice, cannot be justified by the pending status of further evidence. What EBM frames as scientific caution reads, from this architecture, as a failure to act on what is already known. See The Instruments Already Exist for the fuller reading of GC14 and the operationalisation precedents in international health law, and A Litigation Brief for the analytical frame a jurist would use to bring these instruments to bear on a specific case.